AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04589234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmonella-IL2
Description: Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
Study NCT04589234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX Alone (Historical Controls)
Description: We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
Study NCT04589234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Abraxane Alone (Historical Controls)
Description: We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group
Study NCT00394277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
Study NCT03292159 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive RAVANS concurrent with arm motor training
Description: Patient does not receive stimulation delivered to the skin of left outer ear while participating in arm motor training
Study NCT03786718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-facing Diabetes Dashboard
Description: The Patient-facing Diabetes Dashboard is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy level appropriate educational resources, and contains secure-messaging capability.
Study NCT03193073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: detailed echocardiography
Description: Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
Study NCT03833115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaginal gel containing or not sodium lauryl sulfate
Description: Prevention
Study NCT01849575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2-4 weeks a follow-up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.~CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period.
Study NCT05007899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Alternate day dosing of ferrous sulfate
Study NCT03861351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini WELL Toric Ready intraocular lens
Description: The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.
Study NCT03193073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum fibroblast growth factor-23
Description: serum levels of FGF-23
Study NCT03193073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: flow mediated dilatation of forearm
Description: superficial sonar assess the diameter of brachial vessel on exposure to stress
Study NCT06200324 — intervention group
Intervention type: OTHER
Intervention: Ready-to-Use Parenteral Nutrition
Description: In newborns weighing less than 1000 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum volume of 128 ml/kg/day, with a provision of 4 grams/kg/day of protein and a metabolic rate of 12 mg/kg/minute.~For newborns weighing between 1001-1500 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum of 110 ml/kg/day.~When enteral intake exceeds 70 ml/kg/day, a gradual decrease in the volume of parenteral nutrition is initiated. We discontinue parenteral nutrition in newborns weighing less than 1000 grams with enteral volume of 120 ml/kg/day, and for those between 1000 grams and 1500 grams, enteral nutrition volume of 100 ml/kg/day.
Study NCT02727751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Study NCT02374801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonR automatic optimization feature turned ON (AV+VV).
Study NCT05007899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Alternate day dosing of ferrous sulfate
Study NCT04595461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard patient education with verbal and written education
Study NCT01082575 — intervention group
Intervention type: DEVICE
Intervention: Oxygen Monitoring
Description: No intervention
Study NCT01959854 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose
Description: 0.25% carboxymethylcellulose preservative free
Study NCT01959854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: xanthan gum
Description: 0.2% xanthan gum preservative free
Study NCT01557036 — intervention group
Intervention type: DEVICE
Intervention: Pipeline Embolization Device
Description: Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
Study NCT03124017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart
Study NCT01629589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)
Description: 0.5 mL, Intramuscular
Study NCT01629589 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)
Description: 0.5 mL, Intramuscular
Study NCT02336958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intermediate cervical plexus block ropivacaine
Description: 20ml ultrasound guided intermediate cervical plexus block.
Study NCT00151346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and Fentanyl (for CSE)
Description: Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
Study NCT00151346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and Fentanyl (for traditional epidural)
Description: Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
Study NCT03545230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: :Four Not Techniques
Description: :Four Not Techniques~1. Not enter posteriorly~2. Not too much dissection the muscle around the lateral condyle during surgery~3. Not perfect anatomical reduction~4. Not using bone graft.
Study NCT00927394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg tablet
Study NCT00927394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 160 mg capsules
Study NCT00927394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 160 mg capsules
Study NCT00927394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Aliskiren
Description: Placebo for Aliskiren 150 mg tablets
Study NCT00927394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Aliskiren
Description: Placebo for Aliskiren 150 mg tablets
Study NCT00927394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Valsartan
Description: Placebo for Valsartan 160 mg capsules
Study NCT00927394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Valsartan
Description: Placebo for Valsartan 160 mg capsules
Study NCT04400032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Description: The Mesenchymal Stromal Cells will be administered intravenously
Study NCT03878771 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin gel in Orabase
Description: applied on oral mucositis and /or ulcer 3 times per day
Study NCT03878771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dermovate cream in Orabase
Description: applied on oral mucositis and /or ulcer 3 times per day
Study NCT01221363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life style intervention
Description: Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
Study NCT02517463 — intervention group
Intervention type: DRUG
Intervention: Ulipristal acetate
Description: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
Study NCT03476733 — intervention group
Intervention type: OTHER
Intervention: Detection of drug related problem in inpatient
Description: Detection of drug related problem in inpatient
Study NCT01405014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hold Me Tight
Description: Relationship enhancement group
Study NCT00394277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1400-1600 mg po daily for 48 weeks
Study NCT03510026 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Low thermal device preparation
Description: One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
Study NCT04332887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Exercise Program
Description: Patients in the experimental group will receive a 12-week multidimensional exercise program; patients in the control group will maintain their usual life activities.
Study NCT03127683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral position
Description: The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
Study NCT03127683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extension
Description: The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
Study NCT03127683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexion
Description: The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
Study NCT03127683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotation
Description: The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
Study NCT03127683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain TM
Description: Single Use Laryngeal Mask Sterile
Study NCT02336958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intermediate cervical plexus block ropivacaine
Description: 20ml ultrasound guided intermediate cervical plexus block.
Study NCT01382654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine 0.1%
Description: nasal spray 2 sprays to each nostril for a total of 3 doses
Study NCT01382654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine 0.1% with taste masking agent
Description: nasal spray 2 sprays to each nostril for a total for a 3 doses
Study NCT01382654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine 0.2%
Description: nasal spray 2 sprays to each nostril for a total of 3 doses
Study NCT01382654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine 0.2% with taste masking agent
Description: nasal spray 2 sprays to each nostril for a total of 3 doses
Study NCT01382654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine 0.1%
Description: nasal spray 2 sprays to each nostril for a total of 3 doses
Study NCT00522561 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: energetic and non invasive limb mechanical measurements
Description: Force velocity stiffness running
Study NCT03928730 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection and removal
Description: Surgical resection or removal for histopathological examination
Study NCT00720252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
Study NCT03574948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HTP
Description: 8 weeks active substance 5-HTP (2 x 100mg per day)
Study NCT03574948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 8 weeks placebo (2 x 1 caps per day)
Study NCT02119429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pumpkin Seed Oil
Description: 2 grams per day, everyday for 12 weeks.
Study NCT02336958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pericarotidal infiltration (active comparator) ropivacaine
Description: 5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
Study NCT02336958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: jugular infiltration prilocaine
Description: 5ml prilocaine 1% jugular infiltration for wound drainage.
Study NCT02336958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: jugular infiltration prilocaine
Description: 5ml prilocaine 1% jugular infiltration for wound drainage.
Study NCT02119429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Germ Oil
Description: 2 grams per day, everyday for 12 weeks.
Study NCT04150237 — intervention group
Intervention type: OTHER
Intervention: Simulation training in gastroscopy
Description: Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
Study NCT02336958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pericarotidal infiltration (placebo comparator) saline
Description: 5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
Study NCT04185181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality
Description: wii video game based exercise
Study NCT04185181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: proprioceptive neuromuscular facilitation
Description: PNF with breathing
Study NCT04185181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: complete decogestive therapy
Description: pneumatic compression, manual lymph drainage, skin care and home exercise program
Study NCT01834846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-touch
Description: The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
Study NCT01834846 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
Study NCT02974322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Description: GED-0301
Study NCT02974322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03277404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment with smear layer removal
Description: Canal were irrigated with Naocl and EDTA to remove smear layer
Study NCT03277404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment without smear layer removal
Description: only sodium hypochlorite was used for irrigation
Study NCT00603954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conditioning regimen: TBI + Fludarabine
Description: 2 Gy TBI, Fludarabine 90 mg/m²
Study NCT04139629 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: antichlamydial antibody test
Description: At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.
Study NCT04139629 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: treatment of infertility with ART
Description: COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
Study NCT00654394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT03025516 — intervention group
Intervention type: DEVICE
Intervention: Rapid Biosensor Systems (RBS) TB Breathalyser
Description: Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.
Study NCT03025516 — intervention group
Intervention type: DEVICE
Intervention: eNose AeonoseTM
Description: The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
Study NCT01097434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodegradable polymer limus-eluting stents
Description: due randomization biodegradable polymer limus-eluting stents will be implanted
Study NCT01097434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent polymer limus-eluting stent
Description: due randomization permanent polymer limus-eluting stent will be implanted
Study NCT02136316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7962
Description: Oral
Study NCT00603954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conditioning regimen:TLI (8 Gy) + ATG
Description: TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
Study NCT01747707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT01747707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02899455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0904
Study NCT02899455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904
Study NCT02899455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0608
Study NCT02899455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0608
Study NCT02899455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0816
Study NCT02899455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816
Study NCT02899455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0904 Placebo
Study NCT02899455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0816 Placebo
Study NCT04636840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space From Body and Eating Concerns- Teen
Description: Mobile application with coaching component
Study NCT00338728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study NCT00338728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO